Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Recruiting

Phase 3

Zeleciment RostudirsenEfficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Sponsor:

Dyne Therapeutics

Code:

NCT07608432

Conditions

Duchenne Muscular Dystrophy (DMD)

Muscular Dystrophy, Duchenne

Muscular Dystrophy (DMD)

DMD

Muscular Dystrophies

Eligibility Criteria

Sex: Male

Age: 4 - 18

Healthy Volunteers: Not accepted

Interventions

Zeleciment Rostudirsen (DYNE-251)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Dyne Therapeutics on 2026-05-27.